Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Teva Announces Purchase Of 51% Equity Share Of Genomic-Analysis Company

Transaction underscores Teva’s “personalized-medicine” approach to treatment optimization across a spectrum of specialty and generics development programs and lifecycle management initiatives Teva gains exclusive rights to Immuneering’s cutting-edge analytics to advance treatments for diseases of the CNS   JERUSALEM & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and privately-held Immuneering Corporation today […]

Read More »

AstraZeneca PLC Pays Isis Pharma $65 Million Upfront in Antisense Drug Pact

August 3, 2015By Alex Keown, BioSpace.com Breaking News Staff CARLSBAD, Calif. – Isis Pharmaceuticals, Inc. (ISIS) and AstraZeneca PLC (AZN) inked a deal to develop antisense therapies for cardiovascular, metabolic and renal diseases, the companies jointly announced this morning. This marks a continued trend for Isis to collaborate with a large pharmaceutical company to develop […]

Read More »

AstraZeneca Halts Three Clinical Trial Programs, Reports Six Quarters of Top-line Growth

At the very end of its 2015 half-year financial report, on page 49, AstraZeneca PLC (AZN) noted the termination of three projects between April 1 and June 30. They were a program for selumetinib for uveal melanoma, tenapanor for ESRD-pi/CKD with T2DM and Nexium for refractory reflux esophagitis. The selumetinib and tenapanor programs were halted […]

Read More »

Healthcare deals lift July to 7th busiest M&A month on record

A surge of takeover activity involving healthcare, financial and retail companies lifted the value of deals in July over $430 billion, making it the seventh-busiest mergers and acquisition month on record, Thomson Reuters data showed. A total of $436.4 billion worth of deals had been concluded as of July 30, including 14 bumper deals worth […]

Read More »

Amneal to Create Up to 300 Jobs at Former Johnson & Johnson Site in Ireland

US-headquartered generic drug manufacturer Amneal Pharmaceuticals is to create up to 300 jobs in Tipperary following its acquisition of the former Johnson & Johnson plant in Cashel. The 200,000 square foot facility was sold to Amneal by Singapore-based investment firm Solidus Private Equity. The former Johnson & Johnson plant had been vacant for four years […]

Read More »

Watch Out Gilead, Investors Feel Vertex May Be Biogen’s Good Fit

July 31, 2015By Alex Keown, BioSpace.com Breaking News Staff CAMBRIDGE, Mass. – A Bloomberg survey of 30 investors indicates Biogen (BIIB) needs to enter the M&A fray sooner than expected in order to boost revenue, the business site reported this morning. Asthika Goonewardene, a health-care analyst for Bloomberg Intelligence, said the Boston-based drugmaker should acquire […]

Read More »

Despiting Ramping Up In-House R&D, Eli Lilly and Pfizer Remain Committed to CROs

July 31, 2015By Alex Keown, BioSpace.com Breaking News Staff CHICAGO – Despite Pfizer’s (PFE) and Eli Lilly and Company’s (LLY) expansion of research and development facilities, the two major pharmaceutical companies say they both plan on continuing to use contract research organizations (CRO), Outsourcing-Pharma reported this morning. Earlier this month, Pfizer announced plans to consolidate […]

Read More »

Takeda Reports 1st Quarter Results Of FY2015 With Underlying Revenue Growth Of +6.1%

OSAKA, Japan, July 30, 2015 /PRNewswire/ — Guidance for FY2015 confirmed, including Core Earnings and Core EPS Highlights of Q1 results • Underlying revenue +6.1% year-to-year (reported revenue growing +8.5% to 446.3 billion yen)•Underlying core earnings and underlying core EPS were flat, year-to-yearGrowth supported by innovative new products •The growth of new products was sufficient […]

Read More »

Amgen Raises 2015 Outlook, Results Beat Expectations

Amgen Inc. raised its 2015 guidance after reporting that its second-quarter earnings rose 6.9% on better-than-expected sales growth and lower operating expenses. For the year, the biotechnology company now expects per-share earnings of $9.55 to $9.80 and revenue of $21.1 billion to $21.4 billion, compared with its previously boosted estimate for per-share profit of $9.35 […]

Read More »

Abbott strikes deals with heart valve replacement companies

Abbott Laboratories (ABT.N) on Thursday said it would buy a small private company and has invested in another, with an option to buy, as it places bets on the future growth potential of minimally invasive systems to replace diseased heart valves. Abbott said it has agreed to acquire the equity in Minnesota-based Tendyne Holdings Inc […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom